Do analysts rate CMND or PHIO?

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,300.00%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Clearmind Medicine. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, CMND or PHIO?

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clearmind Medicine N/A N/A -$3.86M -$139.98 N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A

Is CMND or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat Clearmind Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Clearmind Medicine N/A -143.79% -88.51% Phio Pharmaceuticals N/A -77.34% -70.87%

Which has stronger earnings & valuation, LIAN or CMND?

LianBio is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Clearmind Medicine N/A N/A -$3.86M -$139.98 N/A

Is LIAN or CMND more profitable?

LianBio's return on equity of -33.17% beat Clearmind Medicine's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Clearmind Medicine N/A -143.79% -88.51%

Do analysts recommend GDTC or CMND?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, GDTC or CMND?

CytoMed Therapeutics has higher revenue and earnings than Clearmind Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CytoMed Therapeutics $324.39K 35.60 -$3.10M N/A N/A Clearmind Medicine N/A N/A -$3.86M -$139.98 N/A

Is GDTC or CMND more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Clearmind Medicine's return on equity. Company Net Margins Return on Equity Return on Assets CytoMed Therapeutics N/A N/A N/A Clearmind Medicine N/A -143.79% -88.51%

Which has stronger valuation & earnings, CMND or FNCH?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clearmind Medicine N/A N/A -$3.86M -$139.98 N/A Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A

Is CMND or FNCH more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Clearmind Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Clearmind Medicine N/A -143.79% -88.51% Finch Therapeutics Group N/A -69.14% -26.92%

Do analysts rate CMND or KPRX?

Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 280.23%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Clearmind Medicine. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CMND or KPRX more profitable?

Kiora Pharmaceuticals' return on equity of -59.30% beat Clearmind Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Clearmind Medicine N/A -143.79% -88.51% Kiora Pharmaceuticals N/A -59.30% -41.23%

Clearmind Medicine (CMND) Competitors

$2.36 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.33 -0.03 (-1.40%)

As of 07/2/2026 07:58 PM Eastern

Compare

CMND vs. PHIO, LIAN, GDTC, FNCH, and KPRX

Should you buy Clearmind Medicine stock or one of its competitors? MarketBeat compares Clearmind Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clearmind Medicine include Phio Pharmaceuticals (PHIO), LianBio (LIAN), CytoMed Therapeutics (GDTC), Finch Therapeutics Group (FNCH), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry.

How does Clearmind Medicine compare to Phio Pharmaceuticals?

Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Clearmind Medicine has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

Phio Pharmaceuticals' return on equity of -77.34% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-143.79%	-88.51%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,300.00%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Clearmind Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearmind Medicine	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Clearmind Medicine and Clearmind Medicine both had 1 articles in the media. Phio Pharmaceuticals' average media sentiment score of 1.00 beat Clearmind Medicine's score of 0.52 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Clearmind Medicine	Positive
Phio Pharmaceuticals	Positive

Summary

Phio Pharmaceuticals beats Clearmind Medicine on 9 of the 12 factors compared between the two stocks.

How does Clearmind Medicine compare to LianBio?

LianBio (NASDAQ:LIAN) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

In the previous week, Clearmind Medicine had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for Clearmind Medicine and 0 mentions for LianBio. Clearmind Medicine's average media sentiment score of 0.52 beat LianBio's score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
Clearmind Medicine	Positive

LianBio is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A

74.8% of LianBio shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

LianBio's return on equity of -33.17% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Clearmind Medicine	N/A	-143.79%	-88.51%

Summary

Clearmind Medicine beats LianBio on 6 of the 10 factors compared between the two stocks.

How does Clearmind Medicine compare to CytoMed Therapeutics?

CytoMed Therapeutics (NASDAQ:GDTC) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Clearmind Medicine had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 1 mentions for Clearmind Medicine and 0 mentions for CytoMed Therapeutics. Clearmind Medicine's average media sentiment score of 0.52 beat CytoMed Therapeutics' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
CytoMed Therapeutics	Neutral
Clearmind Medicine	Positive

CytoMed Therapeutics has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

CytoMed Therapeutics has higher revenue and earnings than Clearmind Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$324.39K	35.60	-$3.10M	N/A	N/A
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Clearmind Medicine	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

CytoMed Therapeutics' return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
Clearmind Medicine	N/A	-143.79%	-88.51%

Summary

CytoMed Therapeutics beats Clearmind Medicine on 5 of the 9 factors compared between the two stocks.

How does Clearmind Medicine compare to Finch Therapeutics Group?

Clearmind Medicine (NASDAQ:CMND) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

Finch Therapeutics Group's return on equity of -69.14% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-143.79%	-88.51%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

In the previous week, Clearmind Medicine had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for Clearmind Medicine and 0 mentions for Finch Therapeutics Group. Clearmind Medicine's average media sentiment score of 0.52 beat Finch Therapeutics Group's score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Clearmind Medicine	Positive
Finch Therapeutics Group	Neutral

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Clearmind Medicine has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Summary

Clearmind Medicine and Finch Therapeutics Group tied by winning 5 of the 10 factors compared between the two stocks.

How does Clearmind Medicine compare to Kiora Pharmaceuticals?

Clearmind Medicine (NASDAQ:CMND) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Clearmind Medicine has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market.

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kiora Pharmaceuticals' return on equity of -59.30% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-143.79%	-88.51%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 280.23%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Clearmind Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearmind Medicine	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Clearmind Medicine had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 1 mentions for Clearmind Medicine and 0 mentions for Kiora Pharmaceuticals. Clearmind Medicine's average media sentiment score of 0.52 beat Kiora Pharmaceuticals' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Clearmind Medicine	Positive
Kiora Pharmaceuticals	Neutral

Clearmind Medicine has higher earnings, but lower revenue than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.71	N/A

Summary

Kiora Pharmaceuticals beats Clearmind Medicine on 8 of the 14 factors compared between the two stocks.

Get Clearmind Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMND vs. The Competition

Export

Metric	Clearmind Medicine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.40M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.02	20.06	28.02	24.70
Price / Sales	N/A	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.21	4.32	10.96	6.46
Net Income	-$3.86M	$64.45M	$3.57B	$337.01M
7 Day Performance	-0.84%	2.97%	2.12%	1.69%
1 Month Performance	-40.70%	6.83%	5.25%	3.81%
1 Year Performance	-99.47%	29.07%	33.29%	23.90%

Clearmind Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMND Clearmind Medicine	1.2522 of 5 stars	$2.36 flat	N/A	-99.5%	$2.40M	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	4.1636 of 5 stars	$1.02 -1.9%	$14.00 +1,272.5%	-58.9%	$12.08M	N/A	N/A	10	Positive News High Trading Volume
LIAN LianBio	N/A	$0.11 -13.6%	N/A	-73.5%	$11.97M	N/A	N/A	110
GDTC CytoMed Therapeutics	1.058 of 5 stars	$1.03 +2.0%	N/A	-53.5%	$11.95M	$250K	N/A	N/A	Gap Down High Trading Volume
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMND) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Clearmind Medicine (CMND) Competitors

CMND vs. PHIO, LIAN, GDTC, FNCH, and KPRX

How does Clearmind Medicine compare to Phio Pharmaceuticals?

Summary

How does Clearmind Medicine compare to LianBio?

Summary

How does Clearmind Medicine compare to CytoMed Therapeutics?

Summary

How does Clearmind Medicine compare to Finch Therapeutics Group?

Summary

How does Clearmind Medicine compare to Kiora Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMND vs. The Competition

Clearmind Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Clearmind Medicine (CMND) Competitors

CMND vs. PHIO, LIAN, GDTC, FNCH, and KPRX

How does Clearmind Medicine compare to Phio Pharmaceuticals?

Which has more volatility and risk, CMND or PHIO?

Do insiders & institutionals have more ownership in CMND or PHIO?

Which has preferable earnings and valuation, CMND or PHIO?

Is CMND or PHIO more profitable?

Do analysts rate CMND or PHIO?

Does the media favor CMND or PHIO?

Summary

How does Clearmind Medicine compare to LianBio?

Does the media prefer LIAN or CMND?

Which has stronger earnings & valuation, LIAN or CMND?

Do insiders & institutionals hold more shares of LIAN or CMND?

Which has more risk and volatility, LIAN or CMND?

Is LIAN or CMND more profitable?

Summary

How does Clearmind Medicine compare to CytoMed Therapeutics?

Does the media prefer GDTC or CMND?

Which has more risk and volatility, GDTC or CMND?

Which has stronger valuation and earnings, GDTC or CMND?

Do insiders & institutionals hold more shares of GDTC or CMND?

Do analysts recommend GDTC or CMND?

Is GDTC or CMND more profitable?

Summary

How does Clearmind Medicine compare to Finch Therapeutics Group?

Which has stronger valuation & earnings, CMND or FNCH?

Is CMND or FNCH more profitable?

Does the media favor CMND or FNCH?

Do institutionals and insiders believe in CMND or FNCH?

Which has more risk and volatility, CMND or FNCH?

Summary

How does Clearmind Medicine compare to Kiora Pharmaceuticals?

Which has more risk & volatility, CMND or KPRX?

Do insiders & institutionals have more ownership in CMND or KPRX?

Is CMND or KPRX more profitable?

Do analysts rate CMND or KPRX?

Does the media favor CMND or KPRX?

Which has preferable earnings and valuation, CMND or KPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMND vs. The Competition

Clearmind Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools